書籍詳細

1. MetaHITコンソーシアムによるヒト腸内フローラの解析 ― ヨーロッパプロジェクトの成績と次のステップ ―

P.11 掲載の参考文献

• 1) Junjie Qin et al. A human gut microbial gene cataogue established by metagenomic sequencing, Nature; 464:59-65, 2010
  pubmed

• 2) M. Arumugam et al. Enterotypes of the human gut microbiome, Nature; 473: 174-180, 2011

2. ヒト腸内細菌定着マウスにおける腸管免疫系の成熟-腸内フローラと免疫と健康-

P.17 掲載の参考文献

• 1) Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of thehuman distal gut microbiome. Science; 312: 1355-1359, 2006

• 2) Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell, M, Evans CA, Holt RA, et al. The sequence of the human genome. Science; 291: 1304-1351, 2001
  pubmed

• 3) Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al. Initial sequencing and analysis of the human genome. Nature; 409: 860-921, 2001
  pubmed

• 4) Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature ; 449: 804-810, 2007
  pubmed

• 5) Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habi-tats across space and time. Science; 326: 1694-1697, 2009

• 6) Fletcher CM, Coyne MJ, Villa OF, Chatzidaki-Livanis M, Comstock LE. A general O-glycosylation system important to the physiology of a major human intestinal symbiont. Cell; 137: 321-331, 2009

• 7) Hooper LV: Do symbiotic bacteria subvert host immunity? Nat Rev Microbiol; 7: 367-374, 2009
  pubmed

• 8) Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol; 6: 121-131, 2008
  pubmed

• 9) Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, et al. A core gut microbiome in obese and lean twins. Nature; 457: 480-484, 2009
  pubmed

• 10) Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature; 444: 1027-1031, 2006
  pubmed

• 11) Peterson DA, Frank DN, Pace NR, Gordon JI: Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe; 3: 417-427, 2008
  pubmed

• 12) Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut; 55: 205-211, 2006
  pubmed

• 13) Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA; 104: 13780-13785, 2007
  pubmed

• 14) Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, et al.: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut micro-biota analysis of Crohn disease patients. Proc Natl Acad USA; 105: 16731-16736, 2008

• 15) Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature; 461: 1282-1286, 2009
  pubmed

• 16) Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT: Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5. Science: 2010
  pubmed

• 17) Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol; 19: 59-69, 2007

• 18) Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol; 9: 313-323, 2009
  pubmed

• 19) Klaasen HL, Koopman JP, Van den Brink ME, Bakker MH, Poelma FG, Beynen AC: Intestinal, segmented, filamentous bacteria in a wide range of vertebrate species. Lab Anim; 27: 141-150, 1993

• 20) Obata T, Goto Y, Kunisawa J, Sato S, Sakamoto M, Setoyama H, Matsuki T, Nonaka K, Shibata N, Gohda M, et al. Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc Natl Acad Sci USA; 107: 7419-7424, 2010

3. Clostridium difficile感染と腸内フローラ

P.33 掲載の参考文献

• 1) Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management., Nature Rev Gastroenterol Hetatol; 8: 17-26, 2011

• 2) Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Qjetti V, Cammarota G, Anti M, De Lorenzo A, Pola P, Gasbarrini G, Gasbarrini A. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointesti-nal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther; 15: 163-169, 2001

• 3) Arvola T, Laiho K, Torkkeli S, Mykkanen H, Salminen S, Maunula L, Isolauri E. Prophylactic Lactohacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics; 104: 64, 1999

• 4) Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol; 38: 475-483, 2004
  pubmed

• 5) Brazier JS, Stubbs SL, Duerden BI. Prevalence of toxin A negative/B positive Clostridium difficile strains. J Hosp Infect ; 42: 248-249, 1999
  pubmed

• 6) Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm; 64: 2359-2363, 2007
  pubmed

• 7) Carignan A, Allard C, Pepin J, Cossette B, Nault V, Valiquette L. Risk of Clostridium difficile infection after periopera-tive antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis ; 46: 1838-1843, 2008

• 8) Carroll KC, Bartlett JG. Biology of Clostridium defficile: implications for epidemiology and diagnosis. Annu Rev Microbiol; 65: 501-521, 2011

• 9) Clements ACA, Magalhaes RJS, Tatem AJ, Paterson DL, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis; 10: 395-404, 2010
  pubmed

• 10) Clements ML, Levine MM, Ristaino PA, Daya VE, Hughes TP. Exogenous lactobacilli fed to man. Their fate and ability to prevent diarrheal disease. Prog Food Nutr Sci; 7: 29-37, 1983

• 11) Correa NB, Peret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomizede formula controlled trial of Bifidobacterium lactis and Streptococcus thermophyilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. ; 39: 385-389, 2005
  pubmed

• 12) Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol; 97: 2744-2749, 2002
  pubmed

• 13) Fuller R. Probiotics in man and animals. J Appl Bacteriol. 61989; 6: 365-378

• 14) Gemtsen J, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr; 6: 209-240, 2011

• 15) Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis; 46 (Suppl 1) : S32-S42, 2008

• 16) Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among colinical isolates in an American hospital. J Med Microbiol; 53: 887-894, 2004

• 17) Griesmann T, Guttenberg G, Aktories K. Human alpha-defensins inhibit Clostridium diifficile toxin B. Gastroenterology ; 134: 2049-2058, 2008

• 18) Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. Am J Hosp Pharm. ; 36: 754-757, 1979
  pubmed

• 19) Gough E, Shaikh H, Manges AR. Systemic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis; 53: 994-1002, 2011

• 20) Guo B, Harstall C, Louie T, van Zanten SV, Dieleman LA. Systemc review: faecal transplantation for the treatment of Clostridium defficile-associated disease. Alim Pharmacol Ther; 35: 1-11, 2012

• 21) Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol; 15: 1554-1580, 2009
  pubmed

• 22) Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med; 162: 2177-2184, 2002
  pubmed

• 23) Jirapinyo P, Densupsoontorn N, Thamonsiri N et al. Prevention of antibiotic-associated diarrhea in infants by probiotics. J Med Assoc Thai; 85 (Suppl 2) : S739-S742, 2002

• 24) Kachrimanidou M, Malisiovas N. Clostridium difficile infection: a comprehensive review. Critical Rev Microbiol; 37: 178-187, 2011

• 25) 神谷 茂. 腸管感染症とプロバイオティクス, 医学のあゆみ; 207: 894-898, 2003
  Medical*Online

• 26) 神谷 茂. 強毒型ディフィシル菌感染症の発生とその対策, 日本医事新報 No. 4372, p. 105, 2008

• 27) Kamiya S, Nakamura S. Virulence factors of Clostridium difficile and its pahogenesis in intestinal infection in man. Bifidobacteria Microflora; 12: 1-17, 1993

• 28) Kee VR, Pharm D. Clostridium difficile infection in older adults: a review and update on its management. Am J Geriat Pharmacol; 10: 14-24, 2010

• 29) Kokkotou E, Moss AC, Michos A, Espinoza D, Cloud JW, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of dis-ease recurrence in hamsters. Antimicrob Agents Chemother; 52: 1121-1126, 2008

• 30) Kotowska M, Albrecht P, Szajewska H. Saccharomyces booulardii in the prevention of antibiotic-associated diarrhea in children: arandomized double-blind placebo-controlled trials. Aliment Pharmacol Ther; 21: 583-590, 2005

• 31) Matsuki S, Ozaki E, Shozu M, Inoue M, Shimizu S, Yamaguchi N, Karasawa T, Yamagishi T, Nakamura S. Colonization by Clostridium difficile of neonates in a hospital, and infants and children in three day-care facilities of Kanazawa, Japan. Int Microbiol; 8: 43-48, 2005

• 32) McFarland LV, Surawicz CM, Greenberg RN et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol; 90: 439-448, 1995
  pubmed

• 33) McPherson S, Rees CJ, Ellis R et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent C. difficile diarrhea. Dis Colon Rectum; 49: 640-645, 2006
  pubmed

• 34) Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, Rossignol JF. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis; 43: 421-427, 2006
  pubmed

• 35) Poxton IR, McCoubrey J, Blair G. The pahogenicity of Clostridium difficile. Clin Microbiol Infect; 7: 421-427, 2001

• 36) Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics; 5: 71-86, 2011
  pubmed

• 37) Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, Kurata S: Prevention of antibiotic-associated diarrhea in children by Clostridium hutyricum MIYAIRI. Pediatr lnt; 45: 86-90, 2003

• 38) Sinh P, Bartlett TA, Yun L. Clostridium difficile infection and inflammatory bowel disease: a review. Gastroenterol Res Pract; Article ID136064, 2011

• 39) Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: A meta-analysis of randomized controlled trials. J. Pediatr; 149: 367-372, 2006
  pubmed

• 40) Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. Double blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. Ann Pharm; 24: 382-384, 1990

• 41) Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacilllus GG in the prevention of antibiotic-associated diarrhea in children. J. Pediatrics; 135: 564-568, 1999

• 42) van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: Is donor faeces the solution? Eurosurveillance; 14: 1-6, 2009

• 43) Voth DE, Ballard JD. Clostridium difficile toxins: Mechanism of action and role in disease. Clin Microbiol Rev; 18: 247-263, 2005
  pubmed

• 44) Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerg-ing strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet ; 366: 1079-1084, 2005

• 45) Wunderlich PF, Braun L, Fumagalli I et al. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res; 17: 333-338, 1989
  pubmed

• 46) Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol; 22: 181-215, 2004
  pubmed

• 47) Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis; 45: 302-307, 2007
  pubmed

4. 潰瘍性大腸炎と腸内フローラ

P.47 掲載の参考文献

• 1) Ohkusa T, Sato N, Ogihara T, et al. Fusohacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol; 17: 849, 2002
  pubmed

• 2) Ohkusa T, Okayasu I, Ogihara T, et al. Induction of Experimental Ulcerative Colitis by Fusobacterium varium lsolated from Colonic Mucosa of Patients with Ulcerative Colitis. Gut; 52: 79, 2003

• 3) Nomura T, Ohkusa T, Okayasu I, et al. Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment Pharmacol Ther; 21: 1017, 2005
  pubmed

• 4) Ohkusa T, Nomura T, Terai T, et al. Effectiveness of Antibiotic Combination Therapy in Patients with Active Ulcerative Colitis: A Randomized, Controlled Pilot Trial with Long-Term Follow Up. Scand J Gastroenterol; 40: 1334, 2005
  pubmed

• 5) Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol; 3: 390-407, 2006
  pubmed

• 6) Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: Friend of foe? World J Gastroenterol; 17(5) : 557-566, 2011
  pubmed

• 7) Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature; 474: 307-317, 2011
  pubmed

• 8) Ohkusa T, Okayasu I, Tokoi S, et al. Bacterial invasion into the colonic mucosa in ulcerative colitis. J Gastroenterol Hepatol; 8: 116, 1993
  pubmed

• 9) Singer RE, Buckner BA. Butyrate and propionate: important components of toxic dental plaque extracts. Infect Immun; 32 : 458, 1981
  pubmed

• 10) Popoff MR, Szylit O, Ravisse P, et al. Experimental cecitis in gnotoxenic chickens monoassociated with Clostridium butyricum strains isolated from patients with neonatal necrotizing enterocolitis. Infect Immun; 47: 697, 1985
  pubmed

• 11) Ohkusa T, Yoshida T, Sato N, et al. Commensal bacteria can enter colonic epithelial cells and induce proinfiammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. J Med Microbiol; 58: 535, 2009

• 12) Minami M, Ando T, Okamoto A, et al. Seroprevalence of Fusobacterium varium in ulcerative colitis patients in Japan. FEMS Immunol Med Microbiol; 56: 67-72, 2009
  pubmed

• 13) Andoh A, Sakata S, Koizumi Y, et al. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis; 13: 955-962, 2007
  pubmed

• 14) 大草敏史, 佐藤信紘. ステロイド依存性, 抵抗性の潰瘍性大腸炎に対する抗菌剤多剤併用療法. 消化器科; 40: 366, 2005

• 15) 大草敏史, 原田 章, 佐藤信紘. 潰瘍性大腸炎に対する抗菌剤多剤併用療法の有効性とQOLの向上. 消化器科; 43: 20, 2005

• 16) Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med; 330: 1841, 1994
  pubmed

• 17) Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med; 317: 1625, 1987
  pubmed

• 18) Ohkusa T, Kato K, Terao S, et al. Newly Developed Antibiotic Combination Therapy for Ulcerative Colitis: A Double-Blind Placebo-Controlled Multicenter Trial. Am J Gastroenterol; 105: 1820, 2010
  pubmed

• 19) Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med; 353: 2462, 2005
  pubmed

5. ヒト腸内フローラと健康および病気

P.58 掲載の参考文献

• 1) Ahmed S, GT Macfarlane, A Fite, AJ McBain, P Gilbert and S Macfarlane. Mucosa-Associated Bacterial Diversity in Relation to Human Terminal Ileum and Colonic Biopsy Samples. Appl Environ Microbiol; 73, 2007

• 2) Arumugam M, J Raes, E Pelletier, D Le Paslier, T Yamada, DR Mende, GR Fernandes, T Bruls, J-M Batto, M Bertalan, N Borruel, M Casellas, L Fernandez, L Gautier, T Hansen, M Hattori, T Hayashi, M Kleerebezem, K Kurokawa, M. Leclerc, F Levenez, C Manichanh, HB Nielsen, T Nielsen, N Pons, J Poulain, J Qin, T Sicheritz-Ponten, S Tims, D Torrents, E Ugarte, EG Zoetendal, J Wang, F Guarner, O Pedersen, WM de Vos, S Brunak, J Dore, M Consortium, J Weissenbach, SD Ehrlich and P Bork. Enterotypes of the human gut microbiome. Nature; 473: 174-180, 2011

• 3) Belzer C and WM de Vos. Microbes inside-from diversity to function: the case of Akkermansia. ISME J. epub. 2012

• 4) Booijink CC, EG Zoetendal, M Kleerebezem and WM de Vos. Microbial communities in the human small intestine: cou-pling diversity to metagenomics. Future Microbiol; 2: 285-295, 2007

• 5) Booijink CCGM, S El-Aidy, M Rajilic-Stojanovic, HGH. J Heilig, FJ Troost, H Smidt, M Kleerebezem, WM de Vos and EG Zoetendal. High temporal and inter-individual variation detected in the human ileal microbiota. Environ Microbiol ; 12: 3213-3227, 2010

• 6) Caporaso JG, J Kuczynski, J Stombaugh, K Bittinger, FD Bushman, EK Costello, N Fierer, AG Pefia, JK Goodrich, JI Gordon, GA Huttley, ST Kelley, D Knights, JE Koenig, RE Ley, CA Lozupone, D McDonald, BD Muegge, M Pirrung, J Reeder, JR Sevinsky, PJ Turnbaugh, WA Walters, J Widmann, T Yatsunenko, J Zaneveld and R Knight. QIIME allows analysis of high-throughput community sequencing data. Nat Methods; 7: 335-336, 2010

• 7) Claesson MJ, O O'Sullivan, Q Wang, J Nikkila, JR Marchesi, H Smidt, WM de Vos, RP Ross and PW O'Toole. Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One; 4: e6669, 2009

• 8) Cole JR, Q Wang, E Cardenas, J Fish, B Chai, RJ Farris, AS Kulam-Syed-Mohideen, DM McGarrell, T Marsh, GM Garrity and JM Tiedje. 2009. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res; 37: D141-D145, 2009

• 9) Derrien M, MC Collado, K Ben-Amor, S Salminen and WM de Vos. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl Environ Microbiol; 74: 1646-1648, 2008

• 10) Derrien M, P Van Baarlen, G Hooiveld, E Norin, M MUller and WM de Vos. Modulation of Mucosal Immune Response, Tolerance, and Proliferation in Mice Colonized by the Mucin-Degrader Akkermansia muciniphila. Front Microbiol ; 2: 166, 2011

• 11) Derrien M, EE Vaughan, CM Plugge and WM de Vos. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol; 54: 1469-1476, 2004

• 12) Dobell, C. Antonie van Leeuwenhoek and his little animals. Harcourt Brace&Company. 1932

• 13) Duncan SH, GE Lobley, G Holtrop, J Ince, AM Johnstone, P Louis and HJ Flint. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes; 32: 1720-1724, 2008

• 14) Eckburg PB, EM Bik, CN Bernstein, E Purdom, L Dethlefsen, M Sargent, SR Gill, KE Nelson and DA Relman. Diversity of the human intestinal microbial flora. Science; 308: 1635-1638, 2005

• 15) Frank DN, AL St Amand, RAB Feldman, ECN Harpaz and NR Pace. Molecular-phylogenetic characterization of micro-bial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA; 104: 13780-13785, 2007

• 16) Franks AH, HJM Harmsen, GC Raangs, GJ Jansen, F Schut and GW Welling. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol; 64: 3336-3345, 1998

• 17) Gill SR, M Pop, RT Deboy, PB Eckburg, PJ Turnbaugh, BS Samuel, JI Gordon, DA. Relman, CM Fraser-Liggett and K. E Nelson. Metagenomic analysis of the human distal gut microbiome. Science; 312: 1355-1359, 2006

• 18) Gloux K, M Leclerc, H Iliozer, RL'Haridon, C Manichanh, G Corthier, R Nalin, HM Blottiere and J. Dore. Development of high-throughput phenotyping of metagenomic clones from the human gut microbiome for modulation of eukaryotic cell growth. Appl Environ Microbiol; 73: 3734-3737, 2007

• 19) Gosalbes M J, A Durban, M Pignatelli, JJ Abellan, N Jimenez-Hernandez, AE Perez-Cobas, A Latorre and A Moya. Metatranscriptomic approach to analyze the functional human gut microbiota. PLoS One; 6: e17447, 2011

• 20) Handelsman, J. Metagenomics: application of genomics to uncultured microorganisms. Microbiol Mol Biol Rev; 68: 669-685, 2004
  pubmed

• 21) Hartman A L, DM Lough, DK Barupal, O Fiehn, T Fishbein, M Zasloff and JA Eisen. Human gut microbiome adopts an alternative state following small bowel transplantation. Proc Natl Acad Sci USA; 106: 17187-17192, 2009

• 22) Hayashi H, R Takahashi, T Nishi, M Sakamoto and Y Benno. Molecular analysis of jejunal, ileal, caecal and recto-sig-moidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism. J Med Microbiol; 54: 1093-1101, 2005

• 23) Jeffery IB, Pw O'Toole, L Ohman, MJ Claesson, J Deane, EM Quigley and M Simren. An irritable bowel syndrome sub-type defined by species-specific alterations in faecal microbiota. Gut epub, 2011

• 24) Jones BV, M Begley, C Hill, CG Gahan and JR Marchesi. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci USA; 105: 13580-13585, 2008

• 25) Klaassens ES, RJ Boesten, M Haarman, J Knol, FH Schuren, EE Vaughan and WM de Vos. Mixed-species genomic microarray analysis of fecal samples reveals differential transcriptional responses of bifidobacteria in breast-and formu-la-fed infants. Appl Environ Microbiol; 75: 2668-2676, 2009

• 26) Klaassens ES, WM de Vos and EE Vaughan. A metaproteomics approach to study the functionality of the microbiota in the human infant gastrointestinal tract. Appl Environ Microbiol; 73: 1388-1392, 2007

• 27) Kolmeder CA, M de Been, J Nikkila, I Ritamo, J Matto, L Valmu, J Salojarvi, A Palva, A Salonen and WM de Vos. Comparative metaproteomics and diversity analysis of human intestinal microbiota testifies for its temporal stability and expression of core functions. PLoS One; 7: e29913, 2012

• 28) Kurokawa K, T Itoh, T Kuwahara, K Oshima, H Toh, A Toyoda, H Takami, H Morita, VK Sharma, TP Srivastava, TD Taylor, H Noguchi, H Mori, Y Ogura, DS Ehrlich, K Itoh, T Takagi, Y Sakaki, T Hayashi and M Hattori. Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res; 14: 169-181, 2007

• 29) Lakhdari O, A Cultrone, J Tap, K Gloux, F Bernard, SD Ehrlich, F Lefevre, J Dore and HM Blottiere. Functional metagenomics: a high throughput screening method to decipher microbiota-driven NF-κB modulation in the human gut. PLoS One; 5: e13092, 2010

• 30) Leimena MM, M Wels, R Bongers, EJ Smid, EG Zoetendal and M Kleerebezem. Comparative analysis of Lactobacillus plantarum WCFS1 transcriptomes using DNA microarray and next generation sequencing technologies. Appl Environ Microbiol, 2012, in press

• 31) Lepage P, P Seksik, M Sutren, MF de la Cochetiere, R Jian, P Marteau and J. Dore. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm. Bowel Dis; 11: 473-480, 2005

• 32) Ley RE, PJ Turnbaugh, S Klein and JI Gordon. Microbial ecology: Human gut microbes associated with obesity. Nature. ; 444: 1022-1023, 2006

• 33) Martinez C, M Antolin, J Santos, A Torrejon, F Casellas, N Borruel, F Guarner and JR Malagelada. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol; 103: 643-648, 2008

• 34) Nelson K E, GM Weinstock, SK Highlander, KC Worley, HH Creasy, JR Wortman, DB Rusch, M Mitreva, E Sodergren, AT Chinwalla, M Feldgarden, D Gevers, BJ Haas, R Madupu, DV Ward, BW Birren, RA Gibbs, B Methe, JF Petrosino, RL Strausberg, GG Sutton, OR White, RK Wilson, S Durkin, MG Giglio, S Gujja, C Howarth, CD Kodira, N Kyrpides, T Mehta, DM Muzny, M Pearson, K Pepin, A Pati, X Qin, C Yandava, Q zeng, L zhang, AM Berlin, L Chen, TA Hepburn, J Johnson, J McCorrison, J Miller, P Minx, C Nusbaum, C Russ, SM Sykes, CM Tomlinson, S Young, WC Warren, J Badger, J Crabtree, VM Markowitz, J Orvis, A Cree, S Ferriera, LL Fulton, RS Fulton, M Gillis, LD Hemphill, V Joshi, C Kovar, M Torralba, KA Wetterstrand, A Abouellleil, AM. Wollam, CJ Buhay, Y Ding, S Dugan, MG FitzGerald, M Holder, J Hostetler, SW Clifton, E Allen-Vercoe, AM Earl, CN Farmer, K Liolios, MG Surette, Q Xu, C Pohl, K Wilczek-Boney and D Zhu. A catalog of reference genomes from the human microbiome. Science; 328: 994-999, 2010

• 35) Parracho HM, MO Bingham, GR Gibson and AL McCartney. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol; 54, 2005

• 36) Png CW, SK Linden, KS Gilshenan, EG Zoetendal, CS McSweeney, LI SIy, MA McGuckin and TH Florin. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol; 105: 2420-2428, 2010

• 37) Qin J, R Li, J Raes, M Arumugam, KS Burgdorf, C Manichanh, T Nielsen, N Pons, F Levenez, T Yamada, DR Mende, J Li, J Xu, S Li, D Li, J Cao, B Wang, H Liang, H Zheng, Y Xie, J Tap, P Lepage, M Bertalan, JM Batto, T Hansen, D Le Paslier, A Linneberg, HB Nielsen, E Pelletier, P Renault, T Sicheritz-Ponten, K Turner, H Zhu, C Yu, S Li, M Jian, Y Zhou, Y Li, X Zhang, S Li, N Qin, H Yang, J Wang, S Brunak, J Dore, F Guarner, K Kristiansen, O Pedersen, J Parkhill, J Weissenbach, M Consortium, P Bork, SD Ehrlich and J Wang. A human gut microbial gene catalogue established by metagenomic sequencing. Nature; 464: 59-65, 2010

• 38) Rajilic-Stojanovic M, E Biagi, HG Heilig, K Kajander, RA Kekkonen, S Tims and WM de Vos Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology ; 141: 1792-1801, 2011

• 39) Rajilic-Stojanovic M, HGHJ Heilig, D Molenaar, K Kajander, A Surakka, H Smidt and WM de Vos. Development and Application of The Human Intestinal Tract Chip(HITChip) , A Phylogenetic Microarray: Absence of Universally Conserved Phylotypes in the Abundant Microbiota of Young and Elderly Adults. Environ Microbiol; 11: 1736-1751, 2009

• 40) Rajilic-Stojanovic M, H Smidt and WM de Vos. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol; 9: 2125-2136, 2007

• 41) Rooijers K, C Kolmeder, C Juste, J Dore, M de Been, S Boeren, P Galan, C Beauvallet, WM de Vos and PJ. Schaap. An iterative workflow for mining the human intestinal metaproteome. BMC Genomics; 12: 6, 2011

• 42) Salonen A, WM de Vos and A Palva. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspec-tives. Microbiology; 156: 3205-3215, 2010

• 43) Schwiertz A, D Taras, K Schafer, S Beijer, NA Bos, C Donus and PD Hardt. Microbiota and SCFA in lean and over-weight healthy subjects. Obesit; 18: 190-195, 2010

• 44) Suau A, R Bonnet, M Sutren, J-J Godon, GR Gibson, MD Collins and J Dore. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol; 65: 4799-4807, 1999

• 45) Swidsinski A, Y Dorffel, V Loening-Baucke, F Theissig, JC Ruckert, M Ismail, WA Rau, D Gaschler, M Weizenegger, S Kuhn, J Schilling and WV Dorffel. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut Epub, 2010

• 46) Turnbaugh PJ, M Hamady, T Yatsunenko, BL Cantarel, A Duncan, RE Ley, ML Sogin, WJ Jones, BA Roe, JP Affourtit, M Egholm, B Henrissat, AC Heath, R Knight and JI Gordon. A core gut microbiome in obese and lean twins. Nature, 457: 480-484, 2009

• 47) Turnbaugh PJ, C Quince, JJ Faith, AC McHardy, T Yatsunenko, F Niazi, J Affourtit, M Egholm, B Henrissat, R Knight, and JI Gordon. Organismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins. Proc Natl Acad Sci USA; 107: 7503-7508, 2010

• 48) van den Bogert B, WM de Vos, EG Zoetendal and M Kleerebezem. Microarray analysis and barcoded pyrosequencing provide consistent microbial profiles depending on the source of human intestinal samples. Appl Environ Microbiol, 77: 2071-2080, 2011

• 49) Van den Bogert B, WM De Vos, EG Zoetendal and M Kleerebezem. Microarray analysis and barcoded pyrosequencing provide consistent microbial profiles depending on the source of human intestinal samples. Appl Environ Microbiol, 77: 2071-2080, 2010

• 50) van Passel MWJ, R Kant, EG Zoetendal, CM Plugge, M Derrien, S Malfatti, P Chain, T Woyke, A Palva, WM de Vos and H Smidt. The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in metamining human microbiomes. PLoS ONE; 6: e16876, 2011

• 51) Verberkmoes NC, AL Russell, M Shah, A Godzik, M Rosenquist, J Halfvarson, MG Lefsrud, J Apajalahti, C Tysk, RL Hettich and JK Jansson. Shotgun metaproteomics of the human distal gut microbiota. ISME J; 3: 179-189, 2009

• 52) Wang M, S Ahrne, B Jeppsson and G Molin. 2005. Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes. FEMS Microbiol Ecol; 54: 219, 2005

• 53) Wang Z, E Klipfell, BJ Bennett, R Koeth, BS Levison, B Dugar, AE Feldstein, EB Britt, X Fu, YM Chung, Y Wu, P Schauer, JD Smith, H Allayee, WH Tang, JA DiDonato, AJ Lusis and SL Hazen. Gut flora metabolism of phosphatidyl-choline promotes cardiovascular disease. Nature; 472: 57-63, 2011

• 54) Willing BP, J Dicksved, J Halfvarson, AF Andersson, M Lucio, Z Zheng, G Jarnerot, C Tysk, JK Jansson and L Engstrand. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterolory; 139: 1844-1854, 2010

• 55) Zoetendal EG, AD Akkermans, WM Akkermans-van Vliet, AJGM de Visser and WM de Vos. The host genotype affects the bacterial community in the human gastrointestinal tract. Microb Ecol Health Dis; 13: 129-134, 2001

• 56) Zoetendal EG, AD Akkermans and WM de Vos. 1998. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol ; 64: 3854-3859, 1998

• 57) Zoetendal EG, CCGM Booijink, ES Klaassens, HGHJ Heilig, M Kleerebezem, H Smidt and WM de Vos. Isolation of RNA from bacterial samples of the human gastrointestinal tract. Nat Protocols; 1: 954-959, 2006

• 58) Zoetendal EG, CM Plugge, ADL Akkermans and WM de Vos. Victivallis vadensis gen. nov., sp. nov., a sugar-ferment-ing anaerobe from human faeces. Int J Syst Evol Microbiol; 53: 211-215, 2003

• 59) Zoetendal EG, J Raes, B van den Bogert, M Arumugam, CC Booijink, FJ Troost, P Bork, M Wels, WM de Vos and M Kleerebezem. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. ISME J epub. 2012

• 60) Zoetendal EG, M Rajilic-Stojanovic and WM de Vos. High throughput diversity and functionality analysis of the gas-trointestinal tract microbiota. Gut; 57: 1605-1615, 2008

• 61) Zoetendal EG, A von Wright, T Vilpponen-Salmela, K Ben-Amor, ADL Akkermans and WM de Vos. Mucosa-associat-ed bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol; 68: 3401-3407, 2002

6. 未知腸内細菌の分離培養とそこから見えてくるもの

P.71 掲載の参考文献

• 1) Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011; 12: 174-180

• 2) Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science; 308: 1635-1638, 2005
  pubmed

• 3) Ley RE, Hamady M, Lozupone C. &8 other authors. Evolution of mammals and their gut microbes. Science; 320: 1647-1651, 2008

• 4) Morotomi M, Nagai F, Sakon H, Tanaka R. Dialister succinatiphilus sp. nov. and Barnesiella intestinihominis sp. nov., isolated from human faeces. Int J Syst Evol Microbiol; 58: 2716-2720, 2008
  pubmed

• 5) Morotomi M, Nagai F, Sakon H, Tanaka R. Paraprevotella clara gen. nov., sp. nov. and Paraprevotella xylaniphila sp. nov., members of the family 'Prevotellaceae' isolated from human faeces. Int J Syst Evol Microbiol; 59: 1895-1900, 2009
  pubmed

• 6) Morotomi M, Nagai F, Watanabe Y, Tanaka R. Succinatillzonas hippei gen. nov., sp. nov., isolated from human faeces. Int J Syst Evol Microbiol; 60: 1788-1793, 2010
  pubmed

• 7) Morotomi M, Nagai F, Watanabe Y. CO2-dependent growth of Succinatimonas hippei YIT 12066T isolated from human feces. Microbiol Immunol, in Press.

• 8) Morotomi M, Nagai F, Watanabe Y. Christensenella minuta gen. nov., sp. nov., isolated from human faeces that forms a distinct branch in the order Clostridiales, and proposal of Christensenellaceae fam. nov. Int J Syst Evol Microbiol; 62: 144-149, 2012
  pubmed

• 9) Morotomi M, Nagai F, Watanabe Y. Parasuttterella secunda sp. nov., isolated from human faeces and proposal of Sutterellaceae fam. nov. in the order Burkholderiales. Int J Syst Evol Microbiol; 61: 637-643, 2011
  pubmed

• 10) Nagai F, Morotomi M, Sakon H, Tanaka R. Parasutterella excrementihominis gen. nov., sp. nov., a member of the family Alcallgenaceae isolated from human faeces. Int J Syst Evol Microbiol; 59: 1793-1797, 2009

• 11) Nagai F, Morotomi M, Watanabe Y, Sakon H, Tanaka R. Alistipes indistinctus sp. nov. and Odoribacter laneus sp. nov., common members of the human intestinal microbiota isolated from faeces. Int J Syst Evol Microbiol; 60: 1296-1302, 2010
  pubmed

• 12) Nagai F, Watanabe Y, Morotomi M. Slackia piriformis sp. nov. and Collinsella tanakaei sp. nov., new members of the family Coriobacteriaceae, isolated from human faeces. Int J Syst Evol Microbiol; 60: 2639-2646, 2010
  pubmed

• 13) Qin J, Li R, Raes J & 51 other authors. A human gut microbial gene catalogue established by metagenomic sequencing. Nature; 464: 59-65, 2010

• 14) Sakon H, Nagai F, Morotomi M, Tanaka R. Sutterella parviruhra sp. nov. and Megamonas funiformis sp. nov., isolated from human faeces. Int J Syst Evol Microbiol; 58: 970-975, 2008
  pubmed

• 15) Tap J, Mondot S, Levenez F & 9 other authors. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol; 11: 2574-2584, 2009

• 16) Turnbaugh PJ, Hamady M, Yatsunenko T. & 12 other authors. A core gut microbiome in obese and lean twins. Nature; 22: 480-484, 2009

• 17) Watanabe Y, Nagai F, Morotomi M, Sakon H, Tanaka R. Bacteroides clarus sp. nov., Bacteroides fluxus sp. nov. and Bacteroides oleiciplenus sp. nov., isolated from human faeces. Int J Syst Evol Microbiol; 60: 1864-1869, 2010
  pubmed

• 18) Watanabe Y, Nagai F, Morotomi M. Characterization of Phascolarctobacterium succinatutens sp. nov., an asaccharolyt-ic, succinate-utilizing bacterium isolated from human feces. Appl Environ Microbiol; 78: 511-518, 2012